Mason Joe's Album: Wall Photos
The gene therapy
market is projected to be worth USD 14.6 billion in 2030, claims Roots
Analysis
Driven by the potential to treat the root cause of
diseases, including rare clinical conditions and those that were previously
deemed incurable, the gene therapies pipeline is growing, and the market
anticipated to witness substantial growth, till 2030
Roots Analysis has announced the addition of “Gene Therapy Market (4th Edition), 2020-2030” report to
its list of offerings.
Success
of approved gene therapies has resulted in a surge in interest of biopharmaceutical
developers in this rapidly evolving domain. Presently, the ability of gene
therapies to treat diverse disease indications is considered among the most
prominent drivers of this market. In addition, promising clinical results of
pipeline candidates are anticipated to draw in more investments to support
product development initiatives.
To order this 720+
page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
Around 800 gene therapies are currently being developed
across different stages
Apart
from 10 approved products, most of the aforementioned therapies (65%) are in
the early stages of development (discovery / preclinical), while the rest are
being evaluated in clinical trials. It is worth mentioning that more than 40%
of clinical stage candidates are intended for the treatment of oncological
disorders.
Over 65% of innovator companies focused on gene therapy
development, are based in North America
Interestingly,
more than 75 players based in the same region, are start-ups, while over 35 are
mid-sized players, and 10 are large and very large firms. Since the majority of
gene therapy developers are headquartered in the US, it is considered a key R&D
hub for such advanced therapy medicinal products.
There are 400+ registered gene therapy focused clinical
trials, worldwide
Clinical
research activity, in terms of number of trials registered, is reported to have
increased at a CAGR of 12% during the period 2015-2020. Of the total number of
trials, close to 25% have already been completed, and 35% claim to be actively
recruiting.
USD 25.4 billion has been invested by both private and
public investors, since 2015
So
far, a significant proportion of the capital raised has been through secondary
offerings (USD 12.9 billion). On the other hand, around USD 5 billion was
invested by venture capital investors, representing 20% of the total amount.
Close to 20,000 patents have been filed / published related
to gene therapies, since 2016
Around
30% of the total number of applications were related to gene editing-based
therapies, while the remaining were associated with gene therapies. Further,
majority of the patent assignees were industry players, however, the contribution
of non-industry players in the overall patent filing activity has increased
considerably (CAGR of 16%), over the past few years.
There have been several mergers and acquisitions in this
market during the period 2015-2019
In
fact, M&A activity is reported to have increased at a CAGR of more than
40%. Key drivers of the acquisitions mentioned in the report include,
therapeutic area expansion, access to a novel technology / platform, drug class
consolidation and drug class expansion.
To request a sample copy / brochure of this report, please
visit this -
https://www.rootsanalysis.com/reports/268/request-sample.html
The report features
inputs from eminent industry stakeholders, according to whom, gene therapies
exhibit the potential to become a promising alternative for the treatment of
genetic disorders. The report includes detailed transcripts of discussions held
with the following experts:
§ Adam
Rogers (CEO, Hemera Biosciences)
§ Al
Hawkins (CEO, Milo Biotechnology)
§ Buel
Dan Rodgers (Founder & CEO, AAVogen)
§ Christopher
Reinhard (CEO & Chairman, Gene Therapeutics (previously known as Cardium
Therapeutics))
§ Michael
Triplett (ex-CEO, Myonexus Therapeutics)
§ Robert
Jan Lamers (ex-CEO, Arthrogen)
§ Ryo
Kubota (CEO, Chairman & President, Acucela)
§ Tom
Wilton (ex-CBO, LogicBio Therapeutics)
§ Jeffrey
Hung (CCO, Vigene Biosciences)
§ Cedric
Szpirer (Executive & Scientific Director, Delphi Genetics)
§ Marco
Schmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager,
PlasmidFactory)
§ Molly
Cameron (Corporate Communications Manager, Orchard Therapeutics)
The research includes
brief profiles of key players (listed below) engaged in the development
of gene therapies; each profile features an overview of the therapy, current
development status, clinical trials and its results (if available), target
indication, route of administration, and recent developments (if available).
§
Abeona Therapeutics
§
Advantagene
§
Biogen
§
bluebird bio
§
Castle Creek Biosciences
§
CG Oncology
§
FerGene
§
Freeline Therapeutics
§
Gradalis
§
Helixmith
§
Inovio Pharmaceuticals
§
Kolon TissueGene
§
Krystal Biotech
§
Lysogene
§
Neurophth Therapeutics
§
OncoSec Immunotherapies
§
Orchard Therapeutics
§
Pfizer
§
Sangamo Therapeutics
§
Spark Therapeutics
§
uniQure Biopharma
§ VBL
Therapeutics
For additional details, please
visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Viral
Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th
Edition), 2021-2030
2.
Global
T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3.
Oncolytic
Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive
Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
market is projected to be worth USD 14.6 billion in 2030, claims Roots
Analysis
Driven by the potential to treat the root cause of
diseases, including rare clinical conditions and those that were previously
deemed incurable, the gene therapies pipeline is growing, and the market
anticipated to witness substantial growth, till 2030
Roots Analysis has announced the addition of “Gene Therapy Market (4th Edition), 2020-2030” report to
its list of offerings.
Success
of approved gene therapies has resulted in a surge in interest of biopharmaceutical
developers in this rapidly evolving domain. Presently, the ability of gene
therapies to treat diverse disease indications is considered among the most
prominent drivers of this market. In addition, promising clinical results of
pipeline candidates are anticipated to draw in more investments to support
product development initiatives.
To order this 720+
page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
Around 800 gene therapies are currently being developed
across different stages
Apart
from 10 approved products, most of the aforementioned therapies (65%) are in
the early stages of development (discovery / preclinical), while the rest are
being evaluated in clinical trials. It is worth mentioning that more than 40%
of clinical stage candidates are intended for the treatment of oncological
disorders.
Over 65% of innovator companies focused on gene therapy
development, are based in North America
Interestingly,
more than 75 players based in the same region, are start-ups, while over 35 are
mid-sized players, and 10 are large and very large firms. Since the majority of
gene therapy developers are headquartered in the US, it is considered a key R&D
hub for such advanced therapy medicinal products.
There are 400+ registered gene therapy focused clinical
trials, worldwide
Clinical
research activity, in terms of number of trials registered, is reported to have
increased at a CAGR of 12% during the period 2015-2020. Of the total number of
trials, close to 25% have already been completed, and 35% claim to be actively
recruiting.
USD 25.4 billion has been invested by both private and
public investors, since 2015
So
far, a significant proportion of the capital raised has been through secondary
offerings (USD 12.9 billion). On the other hand, around USD 5 billion was
invested by venture capital investors, representing 20% of the total amount.
Close to 20,000 patents have been filed / published related
to gene therapies, since 2016
Around
30% of the total number of applications were related to gene editing-based
therapies, while the remaining were associated with gene therapies. Further,
majority of the patent assignees were industry players, however, the contribution
of non-industry players in the overall patent filing activity has increased
considerably (CAGR of 16%), over the past few years.
There have been several mergers and acquisitions in this
market during the period 2015-2019
In
fact, M&A activity is reported to have increased at a CAGR of more than
40%. Key drivers of the acquisitions mentioned in the report include,
therapeutic area expansion, access to a novel technology / platform, drug class
consolidation and drug class expansion.
To request a sample copy / brochure of this report, please
visit this -
https://www.rootsanalysis.com/reports/268/request-sample.html
The report features
inputs from eminent industry stakeholders, according to whom, gene therapies
exhibit the potential to become a promising alternative for the treatment of
genetic disorders. The report includes detailed transcripts of discussions held
with the following experts:
§ Adam
Rogers (CEO, Hemera Biosciences)
§ Al
Hawkins (CEO, Milo Biotechnology)
§ Buel
Dan Rodgers (Founder & CEO, AAVogen)
§ Christopher
Reinhard (CEO & Chairman, Gene Therapeutics (previously known as Cardium
Therapeutics))
§ Michael
Triplett (ex-CEO, Myonexus Therapeutics)
§ Robert
Jan Lamers (ex-CEO, Arthrogen)
§ Ryo
Kubota (CEO, Chairman & President, Acucela)
§ Tom
Wilton (ex-CBO, LogicBio Therapeutics)
§ Jeffrey
Hung (CCO, Vigene Biosciences)
§ Cedric
Szpirer (Executive & Scientific Director, Delphi Genetics)
§ Marco
Schmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager,
PlasmidFactory)
§ Molly
Cameron (Corporate Communications Manager, Orchard Therapeutics)
The research includes
brief profiles of key players (listed below) engaged in the development
of gene therapies; each profile features an overview of the therapy, current
development status, clinical trials and its results (if available), target
indication, route of administration, and recent developments (if available).
§
Abeona Therapeutics
§
Advantagene
§
Biogen
§
bluebird bio
§
Castle Creek Biosciences
§
CG Oncology
§
FerGene
§
Freeline Therapeutics
§
Gradalis
§
Helixmith
§
Inovio Pharmaceuticals
§
Kolon TissueGene
§
Krystal Biotech
§
Lysogene
§
Neurophth Therapeutics
§
OncoSec Immunotherapies
§
Orchard Therapeutics
§
Pfizer
§
Sangamo Therapeutics
§
Spark Therapeutics
§
uniQure Biopharma
§ VBL
Therapeutics
For additional details, please
visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Viral
Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (4th
Edition), 2021-2030
2.
Global
T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition), 2020-2030
3.
Oncolytic
Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive
Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis